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Delayed graft function of more than six days strongly decreases
long-term survival of transplanted kidneys.
Background. We reviewed 843 first cadaver kidney transplants
carried out consecutively at our center to examine the effect on
long-term graft survival of the duration of delayed graft function
(DGF), defined as the time taken for the kidney to attain the
threshold of a Cockcroft calculated creatinine clearance (cCCr) $
10 ml/min.
Methods. Using a multivariate Cox survival analysis we evalu-
ated the consequences of DGF on allograft survival, and then by
regression analysis identified the factors contributing to the
occurrence of DGF. Finally, using a Kaplan Meier analysis we
compared the profiles of graft failure according to the duration of
DGF.
Results. Defining DGF in terms of cCCr rather than necessity for
dialysis after transplantation allowed better prediction of long-
term graft loss. Indeed, patients with a Cockcroft-based DGF .
six days who did not require dialysis (12%) had a significantly
poorer long-term graft outcome than those with a DGF # six
days. Furthermore, we showed that a DGF of six days could be
taken as a cut-off point that marked a significant difference in the
long-term graft survival rate (P , 0.0001). Surprisingly, further
extension of the duration of DGF . six days was not associated
with further worsening of graft survival (except in DGF . 30
days).
Conclusion. Our results suggest a threshold effect in the lesions
that ultimately results in long-term functional deficiency. In
addition, we show that the need for dialysis is not an adequate
criterium for DGF in terms of long-term outcome prediction.
Delayed graft function (DGF) is the most common
complication affecting kidney allografts in the immediate
post-transplant period. Defined as the necessity for dialysis
in the first week after surgery, delayed graft function occurs
in 20% to 50% of patients receiving a first cadaver graft [1,
2]. DGF is usually the result of ischemic damage to the
graft before or during harvesting, and is further aggravated
by the reperfusion syndrome, a multifactorial event in
which polymorphonuclear (PMN) cells play a major role
[reviewed in 3]. DGF, or its experimental counterpart, can
indeed be significantly attenuated by agents that inhibit
PMN/endothelial cell interactions, such as anti-ICAM or
anti-LFA1 monoclonal antibodies, in animals [4] and per-
haps in humans, as we have recently suggested [5]. The role
of DGF in graft survival is controversial. Troppman et al
have suggested that DGF without rejection may have no
impact on long-term graft survival [6]. However, other
reports have shown that DGF and acute rejection episodes
influence graft outcome independently and have additive
adverse effects [7]. To review the impact of DGF on
long-term graft survival and the risk factors for its occur-
rence, we analyzed the case histories of a large adult
population (843 patients) of first cadaver kidney graft
recipients, all transplanted in our department since 1986.
Particular attention was paid to the clinical assessment of
the magnitude of early graft dysfunction. We report here
that defining DGF in terms of the Cockcroft calculated
creatinine clearance (cCCr), rather than in terms of neces-
sity for dialysis after surgery, allowed a better prediction of
long-term graft survival. DGF lasting less than six days was
associated with a highly significant increase (P , 1024) in
long-term graft survival compared to that following a DGF
lasting more than six days.
METHODS
We studied a population of 843 adult patients who had
consecutively received a first cadaver kidney graft at our
center between January 1986 and December 1995. This
time interval was chosen because 1986 was the first year
during which prospective data were recorded and the
various parameters tested below were validated.
Patients
Table 1 shows the demographic characteristics of recip-
ients and donors. All data concerning recipients and donors
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were stored in real time in a computerized database and
were double checked by a clinical research assistant. Data
were then considered valid and were included in the
analysis. Fifty-three patients (6%) were not analyzed for
DGF as a result of (1) immediate vascular thrombosis of
the kidney (24 patients), (2) immediate recurrence of focal
segmental glomerulosclerosis (2 patients) or (3) death (5
patients), during the first week after surgery, or of (4)
missing data (9 patients) and (5) never-functioning kidney
(13 patients, 1.4%).
Definitions of delayed graft function and acute rejection
episodes
DGF is usually defined as the necessity for dialysis during
the first week after transplantation [6, 8]. However, some
patients had to be dialyzed after surgery despite an imme-
diately functioning graft, because of water and electrolyte
imbalances for instance. More frequently, in some recipi-
ents who did have DGF it was possible to avoid dialysis,
because clinical and laboratory parameters remained stable
after surgery despite very low graft function. For these
reasons, DGF for the purposes of this study was defined as
the time required for the kidney to reach a Cockcroft
calculated creatinine clearance (cCCr) $ 10 ml/min, a level
determined empirically as being the threshold for minimal
graft function. The Cockcroft clearance was obtained ac-
cording to the following formula:
@~140 2 age! 3 weight ~kg! 3 F#/@0.814
3 blood creatinine ~mmol/liter!#
where F 5 1.23 for male and 1.04 for female subjects [9,
10]. Therefore a patient who would have reached (that is,
$) 10 ml/min of cCCr at any date after transplantation (of
course, independently from dialysis day values) would be
classified as not having a DGF after this date whatever the
subsequent evolution of his or her graft function.
Acute rejection episodes (AR) were diagnosed on the
grounds of clinical symptoms and confirmed by kidney
biopsy in all cases unless technically impossible. In the
latter event, rejection episodes with intention-to-treat and
response to the treatment were taken into account. acute
rejection episode treatment consisted of intravenous ste-
roid boluses for five days, followed by antithymocyte glob-
ulins (ATG) in the event of steroid resistance (that is,
stable or increased blood creatinine after the last bolus and
absence of histological improvement).
Immunosuppressive therapy
During the study period, several protocols for the induc-
tion of immunosuppression were used. Seventy one percent
(70.8%) of patients were treated from day one (D1) after
surgery with a sequential therapy combining azathioprine
(Aza) at 2 mg/kg/day, steroids at 1 mg/kg/day and either
monoclonal antibodies (anti-CD4 [11], anti-interleukin-2
receptor [12], or anti-LFA1 [5]) or polyclonal antithymo-
cyte globulins (ATG) as induction therapy, followed by
cyclosporine A (CsA) starting at a dose of 8 mg/kg/day for
maintenance therapy. Steroids were tapered off by 10 mg
every five days down to a dose of 10 mg/day, and generally
stopped after three months of follow-up. CsA dosage was
adjusted to yield blood levels of 150 to 250 ng/ml as
measured by monoclonal radioimmunoassay. Aza was
monitored by assessment of white blood cell counts. Only a
minority of patients (9.2%) received the triple regimen of
CsA, steroids and Aza or mycophenolate mofetyl (Cell-
cept®) from D0 after grafting. Finally, 3.2% of patients
received an HLA B2702 derived peptide [13] during the
first 10 days combined with triple therapy (Table 2).
Study variables
The effect on DGF of the following pre- and post-
transplantation parameters were studied: recipient and
donor age and sex, HLA incompatibilities, highest “histor-
ical” level of anti-T panel reactive antibodies (PRA), cold
ischemia time (CIT), requirement of post-transplantation
dialysis, induction therapy with or without CsA from day 1
after surgery and number of acute rejection episodes.
Statistical methods
The Cox semiparametric model was used to evaluate the
influence of pre- and post-transplantation parameters on
graft survival. The logistic regression model was used to
determine the prognostic factors significantly related to
Table 1. Demographic characteristics of the population of the 843 first
kidney cadaver grafts consecutively performed between January 1986
and 1995
Mean recipient age 6 SD (range) 45.7 6 13.2 (18–73)
Mean donor age 6 SD (range) 34.9 6 14.5 (1–69)
Recipient sex 62.2% male
Donor sex 74.2% male
Mean HLA-A-B-DR mismatches 6 SD 3.3 6 1.3
Mean HLA-DR mismatches 6 SD 1.0 6 0.7
PRA (mean of historical maximum) 6 SD 11.2% 6 24.2
Mean cold ischemia time 6 SD (range) hours 34 6 9.8 (5–60)
Mean DGF 6 SD days (range) 7.7 6 7.3 (1–58)
Mean number of post-graft dialyses 6 SD (range) 1.4 6 2.2 (0–16)
Table 2. Distribution of induction regimens administered immediately









ATG 597 (70.8%) 332 (75.1%) 265 (66%)
MoAb (a IL2-R, a CD4,
a LFA1)
147 (17.5%) 81 (18.3%) 66 (16.4%)
CsA 1 CS 1 Aza/MMF 50 (6%) 19 (4.3%) 31 (7.7%)
HLA derived peptide 25 (3.2%) 7 (1.6%) 18 (4.4%)
Others 21 (2.5%) 3 (0.7%) 4 (1%)
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DGF using stepwise selection. For this analysis, a binary
variable was created for DGF, considering the classes
DGF # six days and DGF . six days. The two groups of
patients obtained according to these DFG classes were
then compared using a multivariate analysis of variance,
considering all the prognostic factors globally. On the basis
of the significant overall result, a more detailed analysis was
performed using: (1) a Kaplan-Meier survival analysis
(log-rank test) to compare the profiles of graft failure after
transplantation, (2) Student’s t-test for quantitative param-
eters (taking correction for non-homogeneous variances
into account where necessary), (3) the Wilcoxon non-
parametric test to compare ordinal parameters, and (4) the
Chi-squared test for category parameters. P values less than
0.05 were assumed to indicate a statistically significant
difference. Patients who died during the study were con-
sidered transplant failures.
RESULTS
General incidence of DGF
The mean duration of DGF defined as Cockcroft calcu-
lated clearance threshold of # 10 ml/min was 7.7 6 7.3
(range 1 to 58) days. A total of 47.5% of patients had DGF
longer than one week after surgery, 14.3% longer than two
weeks and only 1.7% longer than one month. The mean
number of dialyses was 1 6 2 (range 0 to 16) and 47% of
patients were dialyzed at least once after transplantation.
The differences resulting from the two methods of assess-
ing DGF are set out below.
Influence of pre- and post-transplantation parameters on
long-term graft survival
Based on the Cockcroft calculated clearance, the results
of the Cox model analysis show that among the parameters
studied, graft loss was strongly associated with DGF (RR 5
1.03, P , 0.0001), recipient age (RR 5 1.017, P , 0.005),
cold ischemia time duration (RR 5 1, P , 0.03), recipient
sex (RR 5 0.63, P , 0.002) and with the occurrence of one
or more acute rejection episodes (RR 5 1.7, P , 0.0001;
Table 3). Because DGF was identified by the Cox model
analysis as a strong prognostic factor for long-term graft
survival, we then built a logistic regression to determine
which variables had independently influenced the occur-
rence of DGF.
Role of pre- and post-transplantation parameters on the
occurrence of DGF
Age (P , 0.0001), cold ischemia time (P , 0.0001), use
of CsA from day 1 after surgery (P , 0.0005) and highest
level of anti-T PRA (P , 0.01) were significantly and
independently correlated to DGF (Table 4).
Impact of short-time DGF on long-term graft function
We then studied the impact of the duration of DGF on
graft survival. A DGF of six days was clearly identified as a
significant threshold by the Kaplan Meier survival analysis
(Fig. 1). DGFs lasting 1, 2, 3, 4, 5 or 6 days resulted in
similar long-term survival rate (Figs. 2 and 3). In addition,
there was no significant difference in graft survival between
DGFs longer than six days, excepted for 10 recipients with
a DGF . 30 days. Patients with a DGF # six days (group
1, N 5 442) had 78% graft survival at 10 years as compared
to 67% when DGF duration was above six days (group 2,
N 5 401; log rank test, P , 0.0001).
Comparison of risk factors according to duration of DGF
The two groups of patients (DGF # or . six days) were
then compared using a multivariate analysis of variance,
globally considering all the parameters studied. As shown
in Table 5, the two populations significantly differed in
terms of donor age, anti-T PRA level, cold ischemia time,
number of acute rejection episodes, and use of CsA from
day 0 after surgery, thus confirming the results obtained in
the logistic regression analysis.
Analysis of DGF according to its definition: cCCr or
requirement of dialysis after surgery
The requirement of at least a dialysis was itself a
prognostic factor of graft survival (log rank test, P , 0.01;
Fig. 4). However, 48 patients (10%) in group 1 (DGF # six
days) were found to have been dialyzed (for hyperkalemia
and/or for water excess) immediately after surgery, showing
that the two definitions overlap in this group of immedi-
ately functioning grafts. However, their 10 years graft
survival was not different with those patients with DGF #
six days who were not dialyzed (log rank test, P , 0.9).
Indeed, in group 2 (DGF . six days), 12.5% of patients
were not dialyzed despite having a Cockcroft DGF longer
than six days. Interestingly, even though the duration of
Table 3. DGF as an independent risk factor for long-term graft
survival: results of the Cox model analysis
Variables Exp(coefficient) (RR) P value
Number of AR episodes 1.762 0.0001
DGF 1.033 0.0001
Recipient age 1.017 0.005
Recipient sex 0.635 0.002
Cold ischemia time 1.000 0.03
Table 4. Description of the variables independently linked to DGF
using logistic regression analysis
Variables P (Chi2) Odds ratio
Donor age 0.0001 0.978
Cold ischemia time 0.0001 0.999
CsA from day 0 0.0005 0.459
Anti-T PRA 0.01 0.992
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DGF (defined in terms of the cCCr threshold of 10 ml/min)
in group 2 was significantly longer (P , 1025) in patients
who required at least one dialysis (14 6 6.5, range 7 to 58
days), than in those who needed no dialysis (10 6 6, range
7–40 days), there was no significant difference between
these two subsets of patients in graft survival rate. More-
over, even in the subset of group 2 patients not requiring
dialysis, graft survival remained significantly lower than in
group 1 patients (P , 0.001). These results suggest, there-
fore, that the requirement of dialyses is inadequate as a
criterion by which to define DGF if the latter is to be seen
in terms of its impact on long-term graft survival. Indeed,
fully 12.5% of patients with DGF . six days (according to
our definition) were not dialyzed, despite being at high risk
of long-term graft loss (Fig. 5). Taken together, that is,
DGF . six days without dialysis requirement and DGF #
six days with dialysis, 22.5% of the entire population did not
correspond to a unique definition of DGF.
DISCUSSION
DGF is high on the list of immediate postoperative
complications of kidney transplantation. Among its clinical
consequences are increased morbidity and cost in the
immediate post-transplantation period, with prolonged
hospital stay and the necessity for substitute dialysis [14].
Furthermore, Hirata, Cecka and Terasaki showed that
patients requiring dialysis because graft function was not
immediate were at a significantly higher risk of death than
patients with immediate graft function [15]. In our popu-
lation of first cadaver graft recipients, multivariate Cox
proportional hazard analysis of graft survival showed that
DGF was an independent risk factor for graft loss, as were
other parameters such as recipient age, one year graft
function and occurrence of acute rejection episodes during
follow-up. DGF itself, as shown by logistic regression, was
independently linked to cold ischemia time, donor and
Fig. 1. Kaplan Meier analysis of graft survival
according to duration of DGF when the cut-off
was at six days: (- - -; N 5 442) group 1 < six
days; ( ; N 5 401) group 2 > six days. The
difference is highly significant (P , 1024).
Fig. 2. Kaplan Meier analysis of graft survival
according to duration of DGF: (. . . . . ; N 5
221) DGFs lasting one day, or (––––; N 5 221)
2, 3, 4, 5 and 6 days, resulted in similar long-
term survival rates. There was no significant
different graft survival for DGFs between 7 to
10 days (– .– .–; N 5 157) and longer than 10
days ( ; N 5 244). However, DGF $ 30 days
were associated with very poor outcome (not
shown).
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recipient age, use of CsA from day 0 and highest level of
anti-T PRA. Some studies have suggested that graft sur-
vival in patients with or without DGF is the same if no
acute rejection episode occurs, but is lower in patients with
both DGF and acute rejection episode when compared to
patients with DGF alone [1, 16, 17]. However, these results
are still controversial, other studies having reported that
acute rejection episode and DGF were independent risk
factors for allograft survival [2, 8, 18–20]. Our analysis
shows that DGF and acute rejection episode are indeed
independent risk factors for graft outcome. Nevertheless,
the incidence of AR episodes was significantly higher in
group 1 with prolonged DGF ($ six days). As other authors
have already pointed out [17], it is possible that the
assessment of DGF and AR could be biased by the
increased number of biopsies performed when DGF is
prolonged, leading to overestimation of the incidence of
AR based on histological changes only. The long term
effect of DGF on graft survival could ultimately be ex-
plained by the subsequent reduction of the nephron mass
leading to hyperfiltration, glomerular hypertension, ne-
phrosclerosis and chronic decline of graft function [3, 21,
22]. It is thus not surprising that donor renal vascular
disease (and related or pre-existing atheromatosis of the
arteries) are independent variables also influencing the
occurrence of DGF by indirectly adding to ischemia/reper-
fusion injury and contributing to the reduction in nephron
mass. CsA treatment has been also shown to be associated
with a reduction in glomerular filtration rate (GFR) that
may result in early renal dysfunction [23]. Interestingly,
although CsA administered immediately after surgery was
indeed linked to an increased frequency of DGF, it did not
affect long-term graft survival. However, it has been sug-
gested that in some specific conditions such as the early
(induction) CsA/OKT3 simultaneous administration, the
presence of CsA could be associated with a decrease in
long-term graft survival, which is an effect that could be
related more to an immunological mechanism than to DGF
[24]. The most surprising point that our study brought to
light was the importance of the criteria used to define DGF.
Fig. 3. Kaplan Meier analysis of graft survival
comparing patients with (. . . . .) an immediate
graft function (that is, < one day; N 5 221) and
with (––––; N 5 442) DGF < six days; ( ;
N 5 401): DGF > six days. There was no
difference between immediate graft function and
DGF # six days in terms of long-term graft
survival.
Table 5. Comparison of variables in group 1 (DGF # 6 days) and group 2 (DGF . 6 days)
Variables
DGF # 6 days
(N 5 442)
DGF . 3 days
(N 5 401) P value
Donor age years mean: 32 6 14 37 6 14 0.0001
Recipient age mean: 45 6 13.7 46.3 6 13 NS
Recipient sex 62.2% male 66% male NS
Donor sex 74.2% male 71% male NS
% of Anti-T PRA 8% 6 21% 13% 6 26% 0.002
% of HLA-A-B-DR mismatches
#2 25.3% 23.2% NS
3/4 56% 57% NS
$5 18.7% 19.8% NS
% of HLA-DR mismatches
0 22% 22.4% NS
1 56% 55% NS
2 22% 22.6% NS
Cold ischemia time mean: 31.5 6 10 hr 36.6 6 9 hr 0.0001
Induction with CsA from D0 10% 17.2% 0.002
Number of AR . 5 1 29% 37.4% 0.01
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Indeed, based on a quantitative assessment of DGF using
the Cockcroft calculated creatinine clearance, we were able
to determine a cut-off point (shorter or longer than six
days) by which to distinguish the population actually “at
high risk” of long term graft dysfunction. In addition, we
found that a significant number of patients with low
function (Cockcroft , 10 ml/min) but who were not
dialyzed was at the same risk as the dialyzed ones, indicat-
ing that the need for dialysis is not adequate to predict the
long term effect of DGF. This also suggests that there is a
threshold effect in the extent of the lesions resulting from
DGF of more than six days and, whatever the duration of
DGF after the first six days, no further significant conse-
quences on graft survival ensued in the analyzed cohort
except for patients with an exceptionally long DGF (.30
days). It therefore seems that DGF of less than six days is
associated with reversible lesions that can undergo com-
plete repair. Additional immunologic or toxic aggression
(PRA, AR, CsA) and other factors that may further
increase the effect of reperfusion injury (cold ischemia
time, donor and recipient age) may lead to more pro-
nounced graft damage with further loss of nephron mass
and exhaustion of functional reserves, resulting ultimately
in premature graft loss.
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Fig. 4. Kaplan Meier graft survival analysis
according to the requirement of at least one
dialysis after graft: ( ; N 5 440) dialysis 5
0; (–––––; N 5 403) dialysis > 1. Patients
needed at least one dialysis after graft had a
significantly lower graft survival than patients
who did not require post-graft dialysis.
Fig. 5. Kaplan Meier graft survival analysis in
patients of group 1 (DGF < six days) as
compared to patients of group 2 (DGF > six
days) without post-graft dialysis (- - - DGF <
six days, N 5 442; —— DGF > six days
without post-graft dialysis, N 5 50). The
outcome of patients with low function
(Cockcroft , 10 ml/min) but without dialysis is
similar to that of patients who needed dialysis.
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